Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT07223385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2026
Completion date
August 31, 2030
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cv risk, prostate cancer (diagnosis), prostate cancer stage iv